Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in:

03-01-2024 | Enzalutamide

Updates on Management of Biochemical Recurrent Prostate Cancer

Authors: Lauren Folgosa Cooley, MD, PhD, Abhishek Srivastava, MD, Neal D. Shore, MD

Published in: Current Treatment Options in Oncology | Issue 3/2024

Login to get access

Opinion Statement

Patients with biochemical recurrent prostate cancer (BCR) are a heterogeneous group, whereby a personalized approach to management is critical. Patients with high-risk features such as PSA doubling time (PSADT) ≤ 9–12 months warrant earlier imaging for metastasis detection and consideration for intensified therapy (beyond intermittent androgen deprivation alone) during this phase of BCR-only disease. The BCR phase represents a unique opportunity to impact disease survival and delay metastasis progression. There is compelling evidence from the EMBARK trial that ADT monotherapy is no longer the optimal consideration for high-risk BCR patients.
Literature
1.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.CrossRefPubMed
2.
Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28(3):555–65.CrossRefPubMed
3.
Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082–90.CrossRefPubMed
4.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.CrossRefPubMed
5.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.CrossRefPubMed
6.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25(13):1765–71.CrossRefPubMed
7.
Spratt DE, McHugh DJ, Morris MJ, Morgans AK. Management of biochemically recurrent prostate cancer: ensuring the right treatment of the right patient at the right time. Am Soc Clin Oncol Educ Book. 2018;38:355–62.CrossRefPubMed
8.
Simon NI, Parker C, Hope TA, Paller CJ. Best approaches and updates for prostate cancer biochemical recurrence. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2022;42:1–8.
9.
de Galiza BF, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;14(20):23.
10.
Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, et al. A Comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients. J Nucl Med Off Publ Soc Nucl Med. 2022;63(4):567–72.
11.
Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43(3):397–403.CrossRefPubMed
12.
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med Off Publ Soc Nucl Med. 2015;56(5):668–74.
13.
Burgard C, Hoffmann MA, Frei M, Buchholz HG, Khreish F, Marlowe RJ, et al. Detection efficacy of 68Ga-PSMA-11 PET/CT in biochemical recurrence of prostate cancer with very low PSA levels: a 7-year, two-center “real-world” experience. Cancers. 2023;15(5):1376.CrossRefPubMedPubMedCentral
14.
• Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, et al. Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol. 2023;84(4):361–70. This reference is of importance as it describes the newest PSMA-targeting radiopharmaceutical approved for use in detecting metastatic prostate cancer by PSMA-PET imaging.CrossRefPubMed
15.
Pinckaers H, van Ipenburg J, Melamed J, De Marzo A, Platz EA, van Ginneken B, et al. Predicting biochemical recurrence of prostate cancer with artificial intelligence. Commun Med. 2022;2(1):1–9.CrossRef
16.
Wei J, Wu X, Li Y, Tao X, Wang B, Yin G. Identification of potential predictor of biochemical recurrence in prostate cancer. Int J Gen Med. 2022;15:4897–905.CrossRefPubMedPubMedCentral
17.
Yoon J, Kim M, Posadas EM, Freedland SJ, Liu Y, Davicioni E, et al. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer Prostatic Dis. 2021;24(3):733–42.CrossRefPubMedPubMedCentral
18.
Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, et al. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. Cancer. 2023;129(14):2169–78.CrossRefPubMed
19.
Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet Lond Engl. 2020;396(10260):1413–21.CrossRef
20.
Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020 21(10):1331–40.
21.
Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341–52.CrossRefPubMed
22.
Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740–9.CrossRefPubMed
23.
Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. The Lancet. 2022;399(10338):1886–901.CrossRef
24.
• Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, et al. Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(6):1307–17. This reference is of importance as it is first to describe the use of enzalutamide vs. androgen deprivation therapy in addition to salvage radiation in men with high-risk biochemical recurrent prostate cancer following surgery. It demonstrates the benefit of enzalutamide + salvage radiation combination in men with pT3 and positive margin status, specifically.CrossRef
25.
Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, et al. Randomized, open-label phase 2 study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer. Prostate Cancer. 2022;2022:5454727.CrossRefPubMedPubMedCentral
26.
•• Freedland SJ, Luz M, Giorgi U, Gleave M, Gotto GT, Piecczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. NEJM. 2023;389(16):1453–65. This reference is of outstanding importance as it is a just-published and practice-changing global, multicenter study (EMBARK) presenting the first utilization and superior efficacy of enzalutamide monotherapy and enzalutamide plus androgen deprivation therapy as compared to androgen deprivation therapy alone in men with high-risk biochemical recurrent prostate cancer.CrossRefPubMed
Metadata
Title
Updates on Management of Biochemical Recurrent Prostate Cancer
Authors
Lauren Folgosa Cooley, MD, PhD
Abhishek Srivastava, MD
Neal D. Shore, MD
Publication date
03-01-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 3/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01164-2

Other articles of this Issue 3/2024

Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?

Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy

Targeting BRCA and PALB2 in Pancreatic Cancer

Preoperative strategies for locally advanced colon cancer

Antiepileptic strategies for patients with brain tumors

Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits